Study Finds Entrectinib Safe, Effective for Patients with Melanoma and Other Cancers

Source: Melanoma News Today, April 2017

Ignyta’s candidate product entrectinib has shown promise as a treatment for several cancer types including melanoma, according to results of two Phase 1 clinical trials.

Treatment with entrectinib was well-tolerated and induced cancer improvement as early as one month after the first treatment, which was sustained for up to 2.5 years in patients with non-small cell lung cancer (NSCLC), colorectal cancer, mammary analog secretory carcinoma (MASC), melanoma and renal cell carcinoma.

Entrectinib is an oral tyrosine kinase (TRK) inhibitor that blocks the proteins TRKA/B/C, ROS1 and ALK, which are all involved in the pathology of certain cancer types.

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories